IGC logo

IGC
IGC Pharma Inc

30,062
Mkt Cap
$26.19M
Volume
91,487.00
52W High
$0.4985
52W Low
$0.242
PE Ratio
-4.29
IGC Fundamentals
Price
$0.2651
Prev Close
$0.2714
Open
$0.27
50D MA
$0.2727
Beta
0.55
Avg. Volume
306,519.05
EPS (Annual)
-$0.0931
P/B
3.39
Rev/Employee
$18,157.14
$21.64
Loading...
Loading...
News
all
press releases
electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of +1.45% and -0.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
More News
News Placeholder
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18d ago
News Placeholder
Merck KGaA (MKKGY) Lags Q4 Earnings Estimates
Merck KGaA (MKKGY) delivered earnings and revenue surprises of -40.43% and +0.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of 0.00% and -56.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of +31.58% and +0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy
IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·5mo ago
News Placeholder
Best Momentum Stocks to Buy for Oct. 24
ASM, IGC and RY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 24, 2025.
Zacks·5mo ago
<
1
2
...
>

Latest IGC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.